key: cord-0900118-wgtwi3cw authors: Hosseini, Faezeh Sadat; Amanlou, Massoud title: Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study date: 2020-08-08 journal: Life Sci DOI: 10.1016/j.lfs.2020.118205 sha: 862d2de94012c5c18991d3ad4799129a24491d43 doc_id: 900118 cord_uid: wgtwi3cw AIMS: Coronavirus disease 2019 (COVID-19) has appeared in Wuhan, China but the fast transmission has led to its widespread prevalence in various countries, which has made it a global concern. Another concern is the lack of definitive treatment for this disease. The researchers tried different treatment options which are not specific. The current study aims to identify potential small molecule inhibitors against the main protease protein of SARS-CoV-2 by the computational approach. MAIN METHODS: In this study, a virtual screening procedure employing docking of the two different datasets from the ZINC database, including 1615 FDA approved drugs and 4266 world approved drugs were used to identify new potential small molecule inhibitors for the newly released crystal structure of main protease protein of SARS-CoV-2. In the following to validate the docking result, molecular dynamics simulations were applied on selected ligands to identify the behavior and stability of them in the binding pocket of the main protease in 150 nanoseconds (ns). Furthermore, binding energy using the MMPBSA approach was also calculated. KEY FINDINGS: The result indicates that simeprevir (Hepatitis C virus NS3/4A protease inhibitor) and pyronaridine (antimalarial agent) could fit well to the binding pocket of the main protease and because of some other beneficial features including broad-spectrum antiviral properties and ADME profile, they might be a promising drug candidate for repurposing to the treatment of COVID-19. SIGNIFICANCE: Simeprevir and pyronaridine were selected by the combination of virtual screening and molecular dynamics simulation approaches as a potential candidate for treatment of COVID-19. Novel coronavirus, designated as SARS-CoV-2, was first identified in December 2019 in Wuhan, China [1] . SARS-CoV-2 belongs to the Coronaviridae (CoV) family, enveloped positive-sense, single-stranded RNA viruses (+ssRNA) that are spread broadly among humans and other mammals which cause a wide range of infections from common cold symptoms to fatal disease like respiratory syndrome. In summery the pathogenesis of SARS-CoV-2 is like this: The envelope spike glycoprotein binds to the ACE2 as a receptor and after membrane fusion, the virus enters to the host cells, RNA genome initiates to translate into structural and non-structural proteins and in the same time the replication of viral genome begins. With the aim of endoplasmic reticulum, the vesicle of the new virus is formed and after fusion to the plasma membrane, the new virus will release. Concurrent the viral entrance to the host cell, its antigen will exposure to antigen presentation cells (APC) and then identified by cytotoxic T lymphocytes (CTLs). But reducing the number of CD4 and CD8 T cells in COVID-19 patients prevents T cell proliferation and activity. The down-regulation in the expression of the APC gene is also possible. Another immunopathological effect is cytokine storm which leads to extensive inflammatory response and multiple organ failure. The IFN-I pathway is also inhibited by this virus [2] . Respiratory Syndrome in 2012 respectively [3] . The fatality rate of SARS-CoV-2 seems to be around 2 percent in China [4] , which is much less than the fatality rate of SARS and MERS. It should be considered that most of the fatal cases are vulnerable people with a medical condition such as immunosuppression, diabetes, or heart disease. Apart from the mortality rate, the point that has made it the global concern is the efficient transmission from human-to-human, leading to its widespread outbreaks in many countries around the world [5] . Up to now, there is no FDA-approved or specific treatment for COVID-19. Clinical guidance of the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), suggested a lot of guidance for treatment including prompt supportive care, oxygen therapy, boosting the immune system, and empiric antimicrobials (in case of sepsis) and others [6] . However, some investigational medication has been suggested for the treatment of COVID-19, such as remdesivir (adenosine triphosphate analog for the treatment of Ebola) or chloroquine (treatment of malaria) [7] and combined HIV protease inhibitor lopinavir-ritonavir One way to overcome the virus replication is to considered essential proteins of the virus as an inhibitory target. One of the most critical proteins for transcription and replication is the main protease of the virus (also known as non-structural protein5, Nsp5), which cleaves the polyproteins into smaller fragments [9] . The main protease monomer has three domains, domain In the current crisis, to achieve a fast and reliable drug for the treatment of COVID-19, we decided to rely on the repurposing concept [12] and consider available FDA and world approved drugs for use in this disease. In this regard, to find potential small molecule inhibitors virtual screening procedure, employing docking of a total of 5881 FDA and world approved drugs over the binding pocket of the main protease protein of SARS-CoV-2 has been done. Afterward, molecular dynamics simulation was performed to validate the docking result and further investigation of the behavior of two selected ligands in a dynamic environment. The binding energy using the MMPBSA approach was also calculated. The results of this study could be promising and may provide a new approach to combat the coronavirus outbreaks. To identify the compounds with the favorable interaction with the main protease of SARS-CoV- crystal structure of SARS-CoV-2 main protease was retrieved from protein data bank (www.rcsb.org) with PDB ID: 6LU7 [13] . AutoDockTools (ADT, Ver.1.5.6) [14] was used for preparing the input files and analyzing the result. For the preparation of protein input files, all water molecules, ligands, and ions were removed from the PDB file. Then polar hydrogens were added and the Kollman-united charge was used to calculate the partial atomic charge and the prepared file was saved in pdbqt format to use in the following steps. 3D structures of FDA and world approved drugs were downloaded from the ZINC database [15] in structure-data file (SDF) format which contains a total of 5881 compounds. All docking results were sorted from the lowest to highest of the docking score. Docking procedures were done automatically by scripts written in-house. Also, docking validation was carried out using previously published methods [17] with re-docking of the co-crystal structure as an inhibitor in the main protease of SARS-CoV-2 with the above-mentioned parameters and values. Visualization of docking results has been done by Discovery Studio visualizer version 17.2 [18] and PyMol version 1.1evel [19] . The best complexes with the lowest docking score were used for further investigation as input files for molecular dynamics simulation. J o u r n a l P r e -p r o o f Journal Pre-proof GROMACS package Version 2020.1 [20] was run on a high-performance Linux cluster to determine the behavior of selected ligands, simeprevir, and pyronaridine in complex with main protease protein of SARS-CoV-2 during the 150 ns. CGenFF web server [21] was used to generate the topology file of the two ligands. From the docking study, the best complex of ligand-protein with the lowest docking score and favorable interactions was selected as an input Surface Area (MM-PBSA) method using g_mmpbsa v2020.1 package by taking snapshots at every 100 ps from 150 ns MDs [22] J o u r n a l P r e -p r o o f In an attempt to find potential treating for COVID-19 from available drugs, molecular docking simulation was performed over 1615 FDA approved and 4266 worlds approved drugs on the binding pocket of the main protease of the virus. Through the docking method, all compounds were compared with each other and the results were sorted from lowest to highest docking score. Each dataset was investigated separately. In FDA approved dataset, the top 25 compounds with lowest docking score were chosen for further investigation and all compounds were evaluated for their clinical applications. According to the reported by WHO and CDC, SARS-CoV-2 mostly affects the respiratory system and leading to symptoms such as fever, cough, and shortness of breath. Therefore, the compounds with specific effects on other systems like the nervous system and skin were omitted (perampanel, thiothixene, and ergotamine). Corticosteroid compounds were omitted because of the special alert by CDC about using them for treatment of viral pneumonia which has no effectiveness and possible harm. Some drugs were ignored because of their side effect (conivaptan and daunorubicin). As a result, after applying these filters there were 10 compounds left which are listed in Table 1 . J o u r n a l P r e -p r o o f Kaposi's sarcoma, cancer of the lung, ovarian, and breast. inhibitors, not only for the main protease but also, 3CL protease and NSP12 RNA polymerase [26] . A drug-target interaction (DTI) deep learning model to predicting available antiviral drugs against SARS-CoV-2 by beck et al, described simeprevir as a potential inhibitor on 3C-like proteinase, helicase and 3'-to-5' exonuclease and endoRNAse [27] . Simeprevir is a broad-spectrum antiviral agent beyond hepatitis C. It can be used in patients with AIDS (Acquired immunodeficiency syndrome) [28] J o u r n a l P r e -p r o o f and other virus infections like HSV-1 (Herpes simplex type 1), ZIKV (Zika virus) and EV-A71 (Enterovirus A71) [29] . The HIV protease inhibitors lopinavir-ritonavir and darunavir, which have suggested as highly effective therapeutic agents against SARS-CoV-2 [8, 25, [30] [31] [32] , showed less docking score -5.36, -5.04 and -7.49 respectively than simeprevir (Table 2 ). Chloroquine and hydroxychloroquine used to treat malaria, systemic lupus erythematosus, rheumatoid arthritis, and Q fever. And through increasing the endosomal pH effects on the SARS-CoV-2 and disrupt virus/cell fusion [7, 33] . But, the docking score of these drugs -7.5 and -6.7 respectively indicates that they do not interact effectively with the main protease. Captopril and enalapril can inhibit the binding between the SARS-CoV-2 and human ACE2, and reduces symptoms of severe pneumonia [34] but based on the obtained docking score -4.22 and -5.6 respectively, these two drugs are not able to interact appropriately with the mentioned target. Subsequently, the top 25 compounds of virtual screening of world approved drug datasets, were investigated. The results were analyzed with the same logic in excluding the FDA-approved drugs, like the affected system and side effects. For example, thioproperazine, Ndesmethyleletriptan, ergoloid, sulforidazine, and other compounds, were excluded from the study because of their particular effects on the nervous system. Testosterone, nandrolone, and abiraterone also omitted. The rest of the compounds listed in Table 3 . The kinase inhibitors to treat cancer, encorafenib and N-Desmethyl imatinib indicate high binding affinity to the active site, but due to their unintended side effects they are not an ideal option for treatment of COVID-19. Regarding tasosartan, probably because of its effect on the angiotensin II (Ang II) receptor and blood pressure, it couldn't be the right choice. The antihistamine agents, rupatadine, mizolastine, and desmethylazelastine could be helpful as symptomatic treatment of shortness of breath. Clofazimine, which used as anti-mycobacterium, anti-trypanosomal [35] , and anticryptosporidium parvum agent [36] may reach the target because of its solubility in fat, and show its inhibitory effect. Pyronaridine, which indicates a high affinity with the lowest docking score - Pyronaridine was synthesized as an antimalarial agent; it has a similar structure to chloroquine but indicates superiority in potency [37] , pharmacokinetic properties, and also less toxicity [38] . Pyronaridine is effective against acute Chagas disease [39] and the Ebola virus (EBOV). Also, its immunomodulation effect during the EBOV infection may synergistically increase its antiviral activity [40] . As long as the Ebola drug like remdesivir and anti-malaria agent like chloroquine can work against coronavirus, therefore pyronaridine which affects both diseases can be promising for the treatment of COVID-19 and could be the ideal compound of this dataset. Finally, remdesivir a prodrug of adenosine nucleotide analog for the treatment of Ebola has entered into clinical phases for COVID-19 [41] . This drug has recently been considered for the J o u r n a l P r e -p r o o f Journal Pre-proof treatment of COVID-19, with its mechanism of action on viral RNA polymerase and making a mistake in proofreading by viral exoribonuclease (ExoN) , which causes a decrease in viral RNA production [42] . The implication stated for the other compounds is also correct here, and docking score -5.8 indicates the inability of this compound to interact well with the main protease binding pocket. However, a promising study has been published that simeprevir suppresses the replication of SARS-CoV-2 in vitro and revealed synergizes with the remdesivir in that way [43] . We can infer that simeprevir and pyronaridine are potential drugs for repurposing in treating COVID-19, due to their favorable interactions with the main protease and also their broadspectrum antiviral activity. Figure 3a illustrates the binding mode of these two drugs in the binding pocket of the main protease. As it clear, the simeprevir placed well in the binding pocket due to its long and flexible structure. To determine the stability and behavior of selected ligands, simeprevir, and pyronaridine in complex with the main protease, molecular dynamics simulations were performed during 150 ns and the analysis was carried out on its output as follows. To ensure the reliability of the results, the simulation of both systems repeated twice. The results of each run presented separately in the supplementary material (Fig. S1-S5) . The backbone root mean square deviation (RMSD) of both complexes was plotted on simulation time. MM-PBSA calculation was performed to account for the binding free energy from three energetic terms. The first term combines the covalent energy, van der Waals and electrostatic interactions of both bonded and non-bonded terms, the second term is solvation free energy and the third is entropy term [44] . The results of the MD, such as stability, the number of hydrogen bonds, and the binding free energy confirmed that simeprevir not only have better docking score but it also retains its interaction and stability over the time. Then it may have more inhibitory effects on the main protease of the virus. J o u r n a l P r e -p r o o f COVID-19 has become a global concern, due to widespread outbreaks and uncertainty in treatment. In this study, we rely on the effectiveness of virtual screening [45] However, simeprevir indicate superiority in many terms, such as interaction with both catalytic residue Cys 145 and His 41 during the time, approved by FDA which confirms its pharmacokinetic or ADME properties, identified as a potential inhibitor by different software for different proteins of the virus, broad-spectrum antiviral activity, low free binding energy, common receptor, the more number of hydrogen bonds and stability during the time and finally its suppression the replication of the virus in in-vitro which makes it a reasonable option for repurposing to the treatment of COVID-19. However, pyronaridine is also a potential choice for the treatment of COVID-19 because of its proper interaction with the receptor and its effectiveness against both malaria and EBOV. Taking together both drugs can be promising for the treatment of COVID-19. Nevertheless, a significant need for clinical approval remains. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia Molecular immune pathogenesis and diagnosis of COVID-19 An Introduction to SARS Coronavirus 2; Comparative Analysis with MERS and SARS Coronaviruses: A Brief Review World Health Organization A novel coronavirus emerging in China-key questions for impact assessment Clinical management of severe acute respiratory infection when novel coronavirus ( 2019-nCoV) infection is suspected: Interim guidance Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Case of the Index Patient Who Caused Tertiary Transmission Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR Substrate specificity profiling and identification of a new class of the SARS coronavirus Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase The drug repurposing landscape from 2012 to 2017: Evolution, challenges, and possible solutions. Drug discovery today Structure of M pro from SARS-CoV-2 and discovery of its inhibitors AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility ZINC 15-ligand discovery for everyone Open Babel: An open chemical toolbox A new insight into mushroom tyrosinase inhibitors: docking, pharmacophore-based virtual screening, and molecular modeling studies The PyMOL Molecular Graphics System. Version 1.1evel, Schröding er GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers Extension of the CHARMM General Force Field to Sulfonyl-Containing Compounds and Its Utility in Biomolecular Simulations Open Source Drug Discovery, C., Lynn, A. g_mmpbsa--a GROMACS tool for highthroughput MM-PBSA calculations Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection Pharmacoinformatics and Molecular Dynamic Simulation Studies Reveal Potential Inhibitors of SARS-CoV-2 Main Protease 3CLpro Repurposing Simeprevir, Calpain Inhibitor IV and a Cathepsin F Inhibitor Against SARS-CoV-2: A Study Using in Silico Pharmacophore Modeling and Docking Methods Comparative Computational Study of SARS-CoV-2 Receptors Antagonists from Already Approved Drugs Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Computational and structural biotechnology journal Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection. Expert review of clinical pharmacology Antiviral effects of simeprevir on multiple viruses Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases. bioRxiv Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. PLoS neglected tropical diseases Activity and pharmacokinetics of a praziquantel crystalline polymorph in the Schistosoma mansoni mouse model Superior pyronaridine single-dose pharmacodynamics compared to artesunate, chloroquine, and amodiaquine in a murine malaria luciferase model Metabolism-dependent neutrophil cytotoxicity of amodiaquine: a comparison with pyronaridine and related antimalarial drugs. Chemical research in toxicology Machine learning models and pathway genome data base for Trypanosoma cruzi drug discovery Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19 Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir Recent developments and applications of the MMPBSA method Virtual screening strategies in drug discovery: a critical review The authors declare no conflict of interest.